Adverum Reports Second Quarter 2021 Results
05 août 2021 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema
22 juil. 2021 16h05 HE
|
Adverum Biotechnologies, Inc.
-- Based on latest analyses, company is revising ADVM-022 development plan to focus on wet AMD and low doses (2 x 10^11 vg/eye and lower); no longer planning development for DME -- -- Company to host...
Adverum Announces Appointment of Jon Williams, Ph.D., as Vice President, Clinical Affairs
01 juil. 2021 08h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Announces Changes to Management Team
24 juin 2021 16h05 HE
|
Adverum Biotechnologies, Inc.
-- Christopher J. DeRespino appointed acting CFO -- -- Peter Soparkar appointed COO -- -- Leone Patterson departs as president and CFO after five years of service -- REDWOOD CITY, Calif., June 24,...
Adverum Appoints CMO and CSO
01 juin 2021 08h00 HE
|
Adverum Biotechnologies, Inc.
-- Julie Clark, M.D., appointed chief medical officer -- -- Brigit Riley, Ph.D., appointed chief scientific officer – REDWOOD CITY, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Adverum...
Adverum Stockholders Re-Elect All Adverum Director Nominees at 2021 Annual Meeting
12 mai 2021 13h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Issues Statement Regarding Upcoming Annual Meeting of Stockholders
10 mai 2021 08h15 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies Inc. (“Adverum”) (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...
Adverum Reports First Quarter 2021 Results
06 mai 2021 16h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021
01 mai 2021 15h26 HE
|
Adverum Biotechnologies, Inc.
-- Long-term durability and maintained efficacy; sustained robust aflibercept protein expression observed -- -- 60% of patients injection free beyond 1 year following 2 x 10^11 single dose -- ...
Adverum Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema
28 avr. 2021 16h01 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony...